January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

Conversely, Stelara, a psoriasis treatment, experienced a 14.7% sales decline to $2.35 billion due to biosimilar competition, although still exceeding analyst predictions of $2.25 billion.

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

The rise in prevalence of psoriasis patients is a significant propellant for the growth of the Stelara ustekinumab market. Psoriasis patients, affected by a chronic autoimmune disorder that ...

Stelara has been a key contributor to the ... JNJ-2113, being developed for multiple indications including ulcerative colitis and psoriasis, is estimated to have peak year sales potential of ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

FYB202 demonstrated comparable efficacy, safety and pharmacokinetics to the reference drug Stelara ® in patients with moderate to severe psoriasis vulgaris (plaque psoriasis). Formycon AG (FSE: FYB) ...